SEC Comment Letter for iBio, Inc. (IBIO) (CIK 0001420720) (IBIO) — Aug 10, 2017
iBio, Inc. (IBIO) (CIK 0001420720)
Date: Aug. 10, 2017 · CIK: 0001420720 · Accession: 0000000000-17-028277
AI Filing Summary & Sentiment
Reasoning
Letter
August 9, 2017 Robert B. Kay Chief Executive Officer iBio, Inc. 600 Madison Avenue, Suite 1601 New York, NY 10022 iBio, Inc. Registration Statement on Form S-1 Filed August 4, 2017 File No. 333-219725Re: Dear Mr. Kay: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at (202) 551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Andrew Abramowitz, Esq.
Show Raw Text
August 9, 2017 Robert B. Kay Chief Executive Officer iBio, Inc. 600 Madison Avenue, Suite 1601 New York, NY 10022 iBio, Inc. Registration Statement on Form S-1 Filed August 4, 2017 File No. 333-219725Re: Dear Mr. Kay: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at (202) 551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Andrew Abramowitz, Esq.